Skip to main content

Table 1 Hazard ratios for disease-free survival of breast cancer

From: The association between the preoperative serum levels of lipocalin-2 and matrix metalloproteinase-9 (MMP-9) and prognosis of breast cancer

  All patients ( N  = 303) Event ( N  = 87) Crude HR (95% CI) P Adjusted HRa(95% CI) P
  N % N %
F/U duration (median), days 67-1930 (1540) 67-1930 (1161)     
Age, mean (SD) 46.6 (10.7) 46.5 (11.4) 0.99 (0.79-1.23) 0.897 1.00 (0.98-1.02) 0.911
  < 39 81 26.7 25 28.7 1.00   1.00  
  40-49 108 35.6 29 33.3 0.85 (0.50-1.46) 0.557 1.21 (0.68-2.16) 0.525
  50 ≤ 114 37.7 33 37.9 0.83 (0.49-1.41) 0.496 0.97 (0.54-1.76) 0.926
Menopausal statusb         
  Premenopausal 191 63.3 54 62.1 1.00   1.00  
  Postmenopausal 111 36.8 33 37.9 1.02 (0.66-1.58) 0.915 1.01 (0.62-1.64) 0.982
BMI, mean (SD) 23.3 (3.17) 23.5 (3.39)     
  < 25 kg/m2 229 75.6 62 71.3 1.00   1.00  
  ≥ 25 kg/m2 74 24.4 25 28.7 1.11 (0.70-1.77) 0.665 1.10 (0.66-1.81) 0.723
TNM stage         
  I 115 38 18 20.7 1.00   1.00  
  IIA -IIB 123 40.5 36 41.4 1.89 (1.06-3.37) 0.031 1.46 (0.78-2.73) 0.242
  IIIA -IIIC 65 21.5 33 37.9 3.97 (2.20-7.13) <.0001 4.41 (2.27-8.57) <.0001
Tumor size         
  < 2 cm 159 52.5 26 29.9 1.00   1.00  
  ≥ 2 cm 144 47.5 61 70.1 2.78 (1.74-4.44) <.0001 2.42 (1.46-4.02) c <.0001
Lymph node status         
  Negative 170 56.1 40 46 1.00   1.00  
  Positive 133 43.9 47 54 1.54 (1.27-1.86) <.0001 1.47 (0.93-2.31) d 0.092
Histologic gradeb         
  I-II 160 55.4 32 39 1.00   1.00  
  III 129 44.6 50 61 2.11 (1.35-3.30) 0.001 1.36 (0.81-2.28) 0.248
Nuclear gradeb         
  I-II 145 54.6 33 39.8 1.00   1.00  
  III 133 45.4 50 60.2 1.96 (1.26-3.06) 0.003 1.16 (0.70-1.95) 0.564
ER status         
  Positive 173 57.1 36 41.4 1.00   1.00  
  Negative 130 42.9 51 58.6 2.40 (1.56-3.70) <.0001 2.34 (1.46-3.75) <.0001
PR status         
  Positive 159 52.5 33 37.9 1.00   1.00  
  Negative 144 47.5 54 62.1 2.19 (1.41-3,.39) 0.001 1.45 (0.79-2.65) 0.235
Adjuvant chemotherapyb        
  Yes 216 72.7 74 87.1 1.00   1.00  
  No 81 27.3 11 12.9 0.34 (0.17-0.65) 0.001 0.61 (0.26-1.41) 0.249
Radiation therapyb         
  Yes 184 61.7 49 57.7 1.00   1.00  
  No 114 38.3 36 42.4 1.26 (0.81-1.94) 0.310 2.08 (1.24-3.49) 0.006
Hormone receptor therapyb        
  Yes 198 66.2 41 47.7 1.00   1.00  
  No 101 33.8 45 52.3 2.65 (1.73-4.06) <.0001 2.03 (0.90-4.60) 0.089
  1. a Adjusted for BMI (< 25 and ≥25 kg/m2), TNM stage (I, II, and III), ER status (positive and negative) and radiation therapy (yes and no).
  2. b Due to missing information, total frequency is less than 303.
  3. c Adjusted for BMI (< 25 and ≥25 kg/m2), lymph node status (yes and no), ER status (positive and negative) and radiation therapy (yes and no).
  4. d Adjusted for BMI (< 25 and ≥25 kg/m2), tumor size (< 2 and ≥2 cm2), ER status (positive and negative) and radiation therapy (yes and no).
  5. HR, hazard ratio; CI, confidence interval; BMI, body mass index; ER, estrogen receptor; PR, progesterone receptor.